Changes in Biomarkers of Cancer in Women With Breast Cancer and Without Evidence of Disease Who Were Given PhytoMed™

Inclusion Criteria:

* Women with histologically confirmed AJCC Stage 0-IIIA breast cancer which has been completely surgically resected.
* No evidence of disease as determined by their physician.
* ER+ and/or PR+ tumour.
* Receiving an aromatase inhibitor (letrozole, anastrazole, exemestane) or tamoxifen at a stable dose for at least 3 months at trial entry.
* Post-menopausal women, defined as: (1) above 50 years of age who have not menstruated during the preceding 12 months or who have follicle-stimulating hormone levels (FSH) \> 40 IU/L, (2) those under 50 years of age who have FSH hormone levels \>40 IU/L, or (3) those who have undergone a bilateral oophorectomy.
* CRP ≥3.9 mg/L measured as the mean of two consecutive weekly tests.
* Aged 18 years or older
* ECOG performance status 0-1
* Between 2 and 5 years from their initial surgery for breast cancer.
* Life expectancy of at least 6 months
* At least 6 months since last chemotherapy
* Laboratory tests performed within 14 days of trial starting:

  1. Granulocytes ≥ 1,500/µL;
  2. Platelets ≥ 100,000/µL;
  3. Haemoglobin ≥ 12.0 g/dL;
  4. Total bilirubin equal to or below upper limit of normal (ULN);
  5. AST and ALT equal to or below ULN;
  6. Alkaline phosphatase equal to or below ULN;
  7. Serum creatinine equal to or below ULN;
* Able to provide informed consent to receive the trial treatment, to provide biological specimens, self-administer oral medica-tion unsupervised for a prolonged period of time, and to complete a medication diary.

Exclusion Criteria:

* Pregnancy or breastfeeding
* Who have had a malignancy (other than breast cancer) which required radiotherapy or systemic treatment within the past 5 years.
* Known cardiac disease (arrhythmias, myocardial infarction, bundle branch block, ischemic heart disease, uncontrolled hypertension)
* Known autoimmune disease or inflammatory disorder
* Any condition requiring the use of systemic corticosteroids or any other immunosuppressive agents (e.g. cyclosporin, tacrolimus, azathioprine).
* Women with known immunodeficiency (such as HIV).
* Patients with infection by septicaemia, infection, acute hepatitis, or other uncontrolled severe medical condition
* Routine use of aspirin \>81 mg/d or NSAIDs (\> 400 mg po 4 times/day of ibuprofen or naproxen \> 500 mg/d) or any use of celecoxib or similar COX-2 inhibitors;
* Subjects are asked not to take dietary supplements, olives or olive oil for 1 month prior to trial enrolment and during the trial.
* Who are taking bisphosphonates